down arrow

Applied Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03828A1016
USD
0.23
0.02 (7.98%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.210.24

52 Week

0.201.50
Valuation
Technical
Day's Volume

CASH

8.55 M

Shareholding (Mar 2025)

FII

12.53%

Held by 60 FIIs

DII

50.9%

Held by 41 DIIs

Promoter

9.55%

How big is Applied Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Applied Therapeutics, Inc. has a market capitalization of 48.84 million, with net sales of 0.26 million and a net profit of -43.50 million over the latest four quarters. The company reported shareholder's funds of 57.01 million and total assets of 86.69 million as of Dec 24.

Market Cap: As of Jun 18, Applied Therapeutics, Inc. has a market capitalization of 48.84 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Applied Therapeutics reported net sales of 0.26 million and a net profit of -43.50 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 57.01 million and total assets of 86.69 million.

Read More

What does Applied Therapeutics, Inc. do?

22-Jun-2025

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. As of March 2025, it has a market cap of $48.84 million and reported a net profit loss of $22 million.

Overview:<BR>Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates targeting unmet medical needs in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -22 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 48.84 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.37<BR>Return on Equity: -287.00%<BR>Price to Book: 1.33<BR><BR>Contact Details:<BR>Address: 545 5TH AVENUE, SUITE 1400, NEW YORK NY: 10017<BR>Tel: 1 212 2209319<BR>Fax: 1 302 6365454<BR>Website: http://www.appliedtherapeutics.com/

Read More

Who are in the management team of Applied Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Applied Therapeutics, Inc. includes Ms. Shoshana Shendelman as Chairman, President, CEO, and Founder, with Dr. Teena Lerner as Lead Independent Director and several Independent Directors including Mr. Leslie Funtleyder, Ms. Stacy Kanter, Mr. Joel Marcus, and Dr. Jay Skyler.

As of March 2022, the management team of Applied Therapeutics, Inc. includes Ms. Shoshana Shendelman, who serves as the Chairman of the Board, President, Chief Executive Officer, and Founder. Additionally, Dr. Teena Lerner is the Lead Independent Director, while Mr. Leslie Funtleyder, Ms. Stacy Kanter, Mr. Joel Marcus, and Dr. Jay Skyler all hold positions as Independent Directors.

Read More

Is Applied Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 7, 2024, Applied Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in a negative ROE of -287.00% and a year-to-date stock decline of 64.96%, contrasting sharply with its peers and the S&P 500.

As of 7 August 2024, the valuation grade for Applied Therapeutics, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its negative performance metrics, including a Price to Book Value of 1.43 and an EV to Sales ratio of 1.93, despite being a loss-making entity with a P/E ratio that cannot be calculated. The ROE stands at a staggering -287.00%, further emphasizing the company's struggles.<BR><BR>In comparison to its peers, Applied Therapeutics shows a stark contrast with Fusion Pharmaceuticals, Inc. and Zevra Therapeutics, both classified as risky, with P/E ratios of -17.58 and -5.05, respectively. The overall peer group reflects a challenging environment, with most companies also facing negative valuations. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date decline of 64.96% compared to a modest gain of 2.44% for the index, reinforcing the notion that Applied Therapeutics is currently overvalued.

Read More

Is Applied Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Applied Therapeutics, Inc. is in a bearish trend, indicated by bearish MACD, moving averages, and RSI, while significantly underperforming the S&P 500 with a year-to-date return of -48.00% compared to the benchmark's 12.22%.

As of 12 September 2025, the technical trend for Applied Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish MACD on the monthly timeframe, bearish moving averages on the daily timeframe, and a bearish RSI on the weekly timeframe. Additionally, the KST and OBV show mixed signals, with the weekly indicators being bullish while the monthly indicators are bearish. <BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -48.00% compared to the S&P 500's 12.22%, and a one-year return of -94.33% versus 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -176.30% of over the last 5 years

 
2

Positive results in Jun 25

3

Risky - Negative EBITDA

4

Reducing Promoter Confidence

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 63 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.72

stock-summary
Return on Equity

-620.25%

stock-summary
Price to Book

3.64

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-55.06%
0%
-55.06%
6 Months
-35.42%
0%
-35.42%
1 Year
-86.4%
0%
-86.4%
2 Years
-90.5%
0%
-90.5%
3 Years
-75.35%
0%
-75.35%
4 Years
-97.85%
0%
-97.85%
5 Years
-98.89%
0%
-98.89%

Applied Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Applied Therapeutics, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Applied Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish MACD on the monthly timeframe, bearish moving averages on the daily timeframe, and a bearish RSI on the weekly timeframe. Additionally, the KST and OBV show mixed signals, with the weekly indicators being bullish while the monthly indicators are bearish. In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -48.00% compared to the S&P 500's 12.22%, and a one-year return of -94.33% versus 17.14% for the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.29%
EBIT Growth (5y)
-176.30%
EBIT to Interest (avg)
-86.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.37
Sales to Capital Employed (avg)
-0.85
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.43
EV to EBIT
-0.02
EV to EBITDA
-0.02
EV to Capital Employed
-0.14
EV to Sales
1.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-287.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 33 Schemes (27.02%)

Foreign Institutions

Held by 60 Foreign Institutions (12.53%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -834.48% vs 109.80% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.00",
          "val2": "-20.30",
          "chgp": "-13.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.40",
          "val2": "22.70",
          "chgp": "-93.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.30",
          "val2": "2.90",
          "chgp": "-834.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-141,944.40%",
          "chgp": "14,194.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -95.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.85% vs -45.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "10.00",
          "chgp": "-95.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.90",
          "val2": "-64.20",
          "chgp": "-61.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.80",
          "val2": "-56.60",
          "chgp": "91.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-105.60",
          "val2": "-119.80",
          "chgp": "11.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-229,228.60%",
          "val2": "-6,458.00%",
          "chgp": "-22,277.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-23.00
-20.30
-13.30%
Interest
0.00
0.00
Exceptional Items
1.40
22.70
-93.83%
Consolidate Net Profit
-21.30
2.90
-834.48%
Operating Profit Margin (Excl OI)
0.00%
-141,944.40%
14,194.44%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -834.48% vs 109.80% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.50
10.00
-95.00%
Operating Profit (PBDIT) excl Other Income
-103.90
-64.20
-61.84%
Interest
0.00
0.00
Exceptional Items
-4.80
-56.60
91.52%
Consolidate Net Profit
-105.60
-119.80
11.85%
Operating Profit Margin (Excl OI)
-229,228.60%
-6,458.00%
-22,277.06%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -95.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.85% vs -45.21% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Applied Therapeutics, Inc. stock-summary
stock-summary
Applied Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).
Company Coordinates stock-summary
Company Details
545 5TH AVENUE, SUITE 1400 , NEW YORK NY : 10017
stock-summary
Tel: 1 212 2209319
stock-summary
http://www.appliedtherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."